GSA Capital Partners LLP Invests $753,000 in Geron Corporation $GERN

GSA Capital Partners LLP bought a new stake in Geron Corporation (NASDAQ:GERN) in the second quarter, HoldingsChannel reports. The fund bought 588,165 shares of the biopharmaceutical company’s stock, valued at approximately $753,000.

Several other hedge funds have also modified their holdings of the stock. LCM Capital Management Inc lifted its position in Geron by 80.6% during the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC purchased a new position in Geron in the 4th quarter worth approximately $33,000. Hsbc Holdings PLC acquired a new stake in Geron in the first quarter valued at approximately $33,000. Caitong International Asset Management Co. Ltd grew its position in Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 24,410 shares in the last quarter. Finally, Amundi purchased a new stake in shares of Geron during the fourth quarter valued at approximately $38,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.00.

Geron Price Performance

Shares of GERN opened at $1.59 on Thursday. Geron Corporation has a 52 week low of $1.04 and a 52 week high of $2.01. The company has a current ratio of 6.91, a quick ratio of 5.16 and a debt-to-equity ratio of 0.55. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -14.45 and a beta of 0.61. The stock has a 50 day moving average of $1.40 and a 200-day moving average of $1.48.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $57.48 million for the quarter, compared to analyst estimates of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. As a group, analysts forecast that Geron Corporation will post -0.04 EPS for the current year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.